WHO Medicines Strategy: Framework for Action in Essential Drugs and Medicines Policy - 2000 - 2003
(2000; 81 pages) [French] Ver el documento en el formato PDF
Índice de contenido
Ver el documentoAcknowledgements
Ver el documentoAbbreviations, Acronyms & WHO Regions
Ver el documentoHighlights - WHO Medicines Strategy: 2000 - 2003
Abrir esta carpeta y ver su contenido1. The Impact of Essential Drugs
Abrir esta carpeta y ver su contenido2. Strategic Directions
Ver el documento3. Core Functions Improving Health Through Knowledge, Advocacy and Partnership
Cerrar esta carpeta4. Country Work - Why and How?
Ver el documento4.1 Country work in context
Ver el documento4.2 How WHO works with countries on medicines
Ver el documento4.3 Types of WHO support
Abrir esta carpeta y ver su contenido5. Framework for Action: Objectives and Expected Outcomes for 2000 - 2003
Abrir esta carpeta y ver su contenido6. Monitoring Progress
Ver el documentoReferences and Notes
 

4.3 Types of WHO support

Of the specific types of support that WHO provides to countries, three involve projects and activities at country level, while a fourth focuses on intercountry, subregional, regional, and interregional programmes and activities (Figure 7).

Evidently, over time, support to countries may shift. For example, specific technical support to a country (type B) may evolve into a comprehensive programme (type C), or vice-versa. In view of WHO's increasing focus on regional and subregional activities, some pharmaceutical technical support to countries (type B) is being shifted to intercountry programmes (type IC), in the form of regional funds. These are managed jointly by the regional adviser and EDM's regional focal point.

WHO's human and financial resources are limited, however. Criteria for country presence are therefore extensive and cover:

• severity of country need
• country's level of development
• potential for success of proposed activities
• potential for sustainable impact of proposed activities
• demonstration or development value of proposed activities
• opportune timing (for example, resources are available or political commitment is strong)
• cost-effectiveness
• funding opportunities
• support to the pharmaceutical sector provided by other agencies or organizations.


Figure 7: WHO pharmaceutical support to countries and regions is adapted according to national and regional need

 

Ir a la sección anterior Ir a la siguiente sección
 

Última actualización: le 19 enero 2012